Dec 19 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA ANNOUNCES INITIATION OF PHASE II OPTION CLINICAL TRIAL OF MS1819-SD IN CYSTIC FIBROSIS PATIENTS.AZURRX BIOPHARMA INC - PLANNED ENROLLMENT IS EXPECTED TO INCLUDE APPROXIMATELY 30 CF PATIENTS, WITH STUDY COMPLETION ANTICIPATED IN 2019.AZURRX BIOPHARMA INC - INITIAL TOP LINE DATA FROM PHASE II OPTION STUDY EXPECTED IN 2019.
Full Article
Dec 12 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA TO ACQUIRE PAYMENT RIGHTS TO LEAD DRUG CANDIDATE MS1819-SD FROM PROTEA BIOSCIENCES GROUP.AZURRX BIOPHARMA INC - WILL PAY A TOTAL OF $1.55 MILLION FOR ASSETS.AZURRX BIOPHARMA INC - WILL ELIMINATE A $2 MILLION MILESTONE PAYMENT THAT WOULD HAVE BEEN DUE TO PROTEA UPON FDA APPROVAL OF MS1819-SD.AZURRX BIOPHARMA - TRANSACTION WAS APPROVED BY JUDGE PATRICK FLATLEY OF U.S. BANKRUPTCY COURT FOR NORTHERN DISTRICT OF WEST VIRGINIA.AZURRX BIOPHARMA - CO WILL NO LONGER BE OBLIGATED TO PAY 2.5% ROYALTY THAT WOULD HAVE BEEN DUE ON 1ST $100 MILLION OF NET SALES OF MS1819-SD.AZURRX BIOPHARMA - DEAL REMOVES REQUIREMENT PROTEA GET 10% OF TOTAL CONSIDERATION FOR MS1819-SD OR CO IF PRODUCT OR PROTEA WERE ACQUIRED BY 3RD PARTY.AZURRX BIOPHARMA - EXPECT TO ANNOUNCE ADDITIONAL KEY MILESTONES BEFORE YEAR-END FOR PHASE 2 STUDY OF MS1819-SD IN CYSTIC FIBROSIS PATIENTS.
Full Article
July 3 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA FILES FOR MIXED SHELF OF UP TO $50 MILLION - SEC FILING.
Full Article
May 11 (Reuters) - AzurRx BioPharma Inc ::LAURENCE W LYTTON REPORTS 6.15 PERCENT PASSIVE STAKE IN AZURRX BIOPHARMA INC AS OF MAY 1 - SEC FILING.
Full Article
Jan 18 (Reuters) - Azurrx Biopharma Inc ::AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY.AZURRX BIOPHARMA INC - IN PARTNERSHIP WITH MAYOLY SPINDLER, RECEIVED REQUIRED APPROVALS TO ADD A FRENCH SITE TO PHASE IIA STUDY OF MS1819-SD.
Full Article
Nov 1 (Reuters) - AzurRx Biopharma Inc :AzurRx Biopharma Inc files for mixed shelf offering of up to $10 million - SEC filing.
Full Article
Oct 20 (Reuters) - Azurrx Biopharma Inc ::Azurrx Biopharma and Mayoly Spindler announce MS1819-SD investigational medicinal product dossier (IMPD) submission.Azurrx Biopharma - IMPD submitted via European Medicines Agency clinical trial portal for approval prior to opening of clinical centers in France.
Full Article
Oct 11 (Reuters) - Azurrx Biopharma Inc :Azurrx biopharma inc files for stock shelf of upto $10 million - sec filing.
Full Article
Earnings vs. 
Estimates